Learn about the global filgrastim biosimilars market through The Business Research Company, which provides information on filgrastim biosimilars market size, filgrastim biosimilars market drivers and restraints, filgrastim biosimilars market players, the COVID-19 impact on the filgrastim biosimilars market, and more.

The global filgrastim biosimilars market size is expected to grow from $0.75 billion in 2021 to $0.88 billion in 2022 at a compound annual growth rate (CAGR) of 17.2%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The filgrastim biosimilars market is expected to reach $1.19 billion in 2026 at a CAGR of 8.0%.

Government initiatives for the development of biosimilars are expected to drive the filgrastim biosimilars market over coming years.

Request A Sample For The Global Filgrastim Biosimilars Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=4016&type=smp

The filgrastim biosimilars market consists of sales of filgrastim biosimilars and related services by entities (organizations, sole traders and partnerships) that manufacture filgrastim biosimilars. Filgrastim biosimilar treatment is used to stimulate the bone marrow to produce more neutrophils (white blood cells) to fight infection in patients undergoing chemotherapy for cancer treatment. Only goods and services traded between entities or sold to end consumers are included.

Global Filgrastim Biosimilars Market Segments Include:

By Application: Oncology, Chronic and Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Infectious Diseases, Others

By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

By Type of Manufacturing: In-House Manufacturing, Contract Manufacturing Organization

By Geography: The market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa. Among these regions, North America was the largest region in the filgrastim biosimilars market in 2021.

Companies in the pegfilgrastim biosimilar market are increasing their product innovation through strategic collaborations. To sustain in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with each other as well as academic and research institutions in this market by way of partnerships, in or out licensing deals, this trend has been increasing over the recent years.

TBRC’s filgrastim biosimilars market report covers:

Major Market Players: Cadila Pharmaceuticals, Dr. Reddy’s Laboratories, Intas Biopharmaceuticals, Sandoz, Amgen Inc., Dr. Reddy’s Laboratories Ltd, Intas Pharmaceuticals, Emcure Pharmaceuticals Ltd., Biocon and Aryogen Biopharma.

Regions: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.

Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Time Series: Five years historic (2016-21) and ten years forecast (2022-2026-2031)

The Filgrastim Biosimilars Global Market Report 2022–Market Size, Trends, And Global Forecast 2022-2026 is one of a series of new reports from The Business Research Company that provides filgrastim biosimilars market overviews, analyses and forecasts market size, share, filgrastim biosimilars market players, filgrastim biosimilars market segments and geographies, leading competitor revenues, profiles and market shares.

TBRC’s filgrastim biosimilars market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.

Here Is A List Of Similar Reports From The Business Research Company:

Biosimilar Growth Hormones Global Market Report 2022

Biosimilar Hormones Global Market Report 2022

Biosimilars Global Market Report 2022

Interested To Know More About The Business Research Company?
The Business Research Company has published over 1000 industry reports, covering over 2500 market segments and 60 geographies. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. The reports are updated with a detailed analysis of the impact of COVID-19 on various markets.

Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow us on LinkedIn: https://in.linkedin.com/company/the-business-research-company
Follow us on Twitter: https://twitter.com/tbrc_info
Check out our Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: